We assessed the efficacy and tolerability of onabotulinumtoxinA @ U vs placebo to treat lower urinary tract symptoms/benign prostatic hyperplasia inmen previously treated with oral benign prostatic hyperplasia medication in a@-week phase @ , multicenter , double-blind , randomized , placebo controlled , parallel group trial .